智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨4.06%，报13.07港元，成交额1.56亿港元。
消息面上，6月9日，再鼎医药首个神经领域产品呫诺美林曲司氯铵胶囊（凯捷乐®）在苏州发货，并向全国多个省市的医院和院外药房供药。当天，该药在首都医科大学附属北京安定医院开出全国首张处方，并于同日惠及全国30余个城市、近50家医院的精神分裂症患者。
此外，再鼎医药日前宣布，国家药品监督管理局（NMPA）已批准缇乐®（注射用维替索妥尤单抗）的生物制品上市许可申请（BLA），用于治疗化疗期间或之后出现进展的复发或转移性宫颈癌成人患者。该获批基于全球、随机对照3期innovaTV 301临床研究结果。维替索妥尤单抗在全球3期innovaTV301临床研究（包括中国亚组数据）中展现出了显著的统计学意义总生存获益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.